Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113455 | 0.80 | MAPK1 (0.44) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL19221486 | 0.80 | SMN1; SMN2 (0.34) | MAPK1TSHRVCAM1POLBALDH1A1 | |
| SCHEMBL29445407 | 0.80 | MAPK1 (0.44) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL12161659 | 0.78 | MAPK1 (0.42) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL9173525 | 0.78 | ALDH1A1 (0.50) | MAPK1TSHRAHRALDH1A1GPR35 | |
| SCHEMBL203312 | 0.78 | INPPL1 (0.46) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL3146522 | 0.77 | GPR35 (0.44) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL126682 | 0.77 | TSHR (0.41) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL5626986 | 0.77 | POLB (0.42) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL2711056 | 0.77 | TSHR (0.41) | MAPK1TSHRAHRCHUKVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1838674-A2 | HETEROARYL SULFONAMIDES AND CCR2 | ChemoCentryx Inc (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CCR2, CXCR2, CCR1 | MAPK1 2619/4885TSHR 1159/4885AHR 63/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | MAPK1 564/4885TSHR 1824/4885AHR 738/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPK1 2691/4885TSHR 1094/4885AHR 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.